Triamcinolone acetonide
Aristocort, Kenacort, Kenalog, Mytrex A, Nasacort, Triamcinolone, Triderm, Triesence, Xipere, Zilretta (triamcinolone acetonide) is a small molecule pharmaceutical. Triamcinolone acetonide was first approved as Aristocort on 1982-01-01. It is used to treat adrenal insufficiency, allergic rhinitis perennial, ankylosing spondylitis, atopic dermatitis, and berylliosis amongst others in the USA. It is known to target glucocorticoid receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Show 7 more
Trade Name
FDA
EMA
Triamcinolone (discontinued: Oralone, Triamcinolone)
CombinationsNystatin triamcinolone (discontinued: Nystatin triamcinolone)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Triamcinolone acetonide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TRIAMCINOLONE ACETONIDE | Mylan | N-011601 DISCN | 1982-01-01 | 2 products, RLD |
| TRIAMCINOLONE ACETONIDE | Rising Pharmaceuticals | N-011600 DISCN | 1982-01-01 | 2 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 24 hour nasal allergy | ANDA | 2026-06-09 |
| allergy nasal | ANDA | 2026-04-07 |
| allergy relief | ANDA | 2026-04-20 |
| allernaze | New Drug Application | 2010-11-23 |
| basic care nasal allergy | ANDA | 2022-10-13 |
| blt-25 kit | unapproved drug other | 2026-01-07 |
| bupivilog kit | unapproved drug other | 2026-01-08 |
| bupivilog procedure kit | New Drug Application | 2014-01-30 |
| calcipotriene 0.005% / triamcinolone acetonide 0.1% | unapproved drug other | 2019-05-10 |
| cortaren corticosteroid/anti-inflammatory system | ANDA | 2022-02-24 |
Show 89 more
Indications
FDA
EMA
Show 22 more
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
TRIAMCINOLONE ACETONIDE, XIPERE, BAUSCH AND LOMB INC | |||
| 2024-10-22 | NP | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Triamcinolone Acetonide, Xipere, Bausch And Lomb Inc | |||
| 9937075 | 2034-05-02 | DP | |
| 9636332 | 2033-11-08 | U-3234 | |
| 8636713 | 2027-05-02 | U-3234 | |
| Triamcinolone Acetonide, Zilretta, Pacira Pharms Inc | |||
| 8828440 | 2031-08-04 | DP | |
| 9555048 | 2031-08-04 | U-2151 | |
| Triamcinolone Acetonide, Triesence, Novartis | |||
| 8128960 | 2029-12-17 | DP | |
| 8211880 | 2029-03-10 | U-1257, U-1258 | |
ATC Codes
A: Alimentary tract and metabolism drugs
— A01: Stomatological preparations
— A01A: Stomatological preparations
— A01AC: Corticosteroids for local oral treatment
— A01AC01: Triamcinolone
C: Cardiovascular system drugs
— C05: Vasoprotectives
— C05A: Agents for treatment of hemorrhoids and anal fissures for topical use
— C05AA: Corticosteroids, topical for treatment of hemorrhoids and anal fissures
— C05AA12: Triamcinolone
D: Dermatologicals
— D07: Corticosteroids, dermatological preparations
— D07A: Corticosteroid dermatological preparations, plain
— D07AB: Corticosteroids, moderately potent (group ii)
— D07AB09: Triamcinolone
— D07B: Corticosteroids, combinations with antiseptics
— D07BB: Corticosteroids, moderately potent, combinations with antiseptics
— D07BB03: Triamcinolone and antiseptics
— D07C: Corticosteroids, combinations with antibiotics
— D07CB: Corticosteroids, moderately potent, combinations with antibiotics
— D07CB01: Triamcinolone and antibiotics
— D07X: Corticosteroids, other combinations
— D07XB: Corticosteroids, moderately potent, other combinations
— D07XB02: Triamcinolone
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H02: Corticosteroids for systemic use
— H02A: Corticosteroids for systemic use, plain
— H02AB: Glucocorticoids, systemic
— H02AB08: Triamcinolone
R: Respiratory system drugs
— R01: Nasal preparations
— R01A: Decongestants and other nasal preparations for topical use
— R01AD: Corticosteroid nasal preparations for topical use
— R01AD11: Triamcinolone
— R03: Drugs for obstructive airway diseases
— R03B: Other drugs for obstructive airway diseases, inhalants in atc
— R03BA: Glucocorticoid inhalants for obstructive airway disease
— R03BA06: Triamcinolone
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01B: Antiinflammatory agents, ophthalmologic
— S01BA: Corticosteroid ophthalmologic antiinflammatory agents, plain
— S01BA05: Triamcinolone
— S02: Otologicals
— S02C: Corticosteroids and antiinfectives in combination, otologic
— S02CA: Corticosteroids and antiinfectives in combination
— S02CA04: Triamcinolone and antiinfectives
Clinical
Clinical Trials
1127 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Macular edema | D008269 | — | — | 14 | 21 | 27 | 7 | 21 | 82 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | 6 | 18 | 13 | 26 | 22 | 78 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | 6 | 17 | 11 | 23 | 24 | 78 |
| Edema | D004487 | — | R60.9 | 10 | 14 | 14 | 3 | 12 | 48 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 21 | 18 | 1 | 11 | 48 |
| Bursitis | D002062 | EFO_1000941 | M71.9 | 2 | 1 | 2 | 5 | 36 | 46 |
| Oral lichen planus | D017676 | — | — | 11 | 9 | 4 | 10 | 9 | 40 |
| Keloid | D007627 | EFO_0004212 | L91.0 | 4 | 9 | 4 | 10 | 14 | 37 |
| Lichen planus | D008010 | — | L43 | 8 | 6 | 2 | 6 | 8 | 29 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | 5 | 10 | 9 | 2 | 6 | 28 |
Show 175 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 7 | 9 | 2 | — | 3 | 17 |
| Graft vs host disease | D006086 | — | D89.81 | 2 | 6 | 3 | — | 2 | 12 |
| Leukemia | D007938 | — | C95 | 4 | 7 | 1 | — | — | 11 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | 6 | 2 | — | — | 9 |
| Hodgkin disease | D006689 | — | C81 | 3 | 5 | 2 | — | — | 8 |
| Cicatrix | D002921 | — | L90.5 | 1 | 2 | 1 | — | 5 | 8 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 3 | 4 | 1 | — | — | 7 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | 5 | 2 | — | 1 | 7 |
| Posterior uveitis | D015866 | EFO_1001119 | — | 1 | 2 | 2 | — | 2 | 6 |
| Gouty arthritis | D015210 | — | — | — | 1 | 4 | — | — | 5 |
Show 78 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | — | 2 | — | — | 4 | 6 |
| T-cell lymphoma | D016399 | — | — | 1 | 5 | — | — | — | 6 |
| Aphthous stomatitis | D013281 | EFO_0003938 | K12.0 | — | 3 | — | — | 2 | 5 |
| T-cell lymphoma cutaneous | D016410 | — | C84.A | 1 | 2 | — | — | 1 | 4 |
| Oral ulcer | D019226 | — | — | — | 1 | — | — | 3 | 4 |
| Therapeutics | D013812 | — | — | — | 1 | — | — | 2 | 3 |
| T-cell lymphoma peripheral | D016411 | — | — | — | 3 | — | — | — | 3 |
| Triple negative breast neoplasms | D064726 | — | — | — | 2 | — | — | 1 | 3 |
| Male breast neoplasms | D018567 | — | — | — | 1 | — | — | 2 | 3 |
| Hematologic neoplasms | D019337 | — | — | 1 | 2 | — | — | — | 3 |
Show 83 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuralgia | D009437 | EFO_0009430 | — | 1 | — | — | — | 3 | 4 |
| Paranasal sinus diseases | D010254 | — | — | 1 | — | — | — | 1 | 2 |
| Glandular and epithelial neoplasms | D009375 | — | — | 2 | — | — | — | — | 2 |
| Myoepithelioma | D009208 | — | — | 2 | — | — | — | — | 2 |
| Laryngeal diseases | D007818 | — | J38.7 | 1 | — | — | — | 1 | 2 |
| Leiomyoma | D007889 | — | D25 | 1 | — | — | — | — | 1 |
| Adenomyosis | D062788 | EFO_1001757 | N80.0 | 1 | — | — | — | — | 1 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | — | — | — | — | 1 |
| Vasoconstriction | D014661 | — | — | 1 | — | — | — | — | 1 |
| Papilledema | D010211 | EFO_1001074 | H35.81 | 1 | — | — | — | — | 1 |
Show 11 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | — | — | 7 | 7 |
| Membranous glomerulonephritis | D015433 | EFO_0004254 | N03.2 | — | — | — | — | 5 | 5 |
| Retinal perforations | D012167 | EFO_1001028 | — | — | — | — | — | 5 | 5 |
| Mastitis | D008413 | EFO_1001034 | N61 | — | — | — | — | 4 | 4 |
| Periodontal diseases | D010510 | — | K05.6 | — | — | — | — | 4 | 4 |
| Granulomatous mastitis | D058890 | — | N61.2 | — | — | — | — | 3 | 3 |
| Physical therapy modalities | D026741 | — | — | — | — | — | — | 3 | 3 |
| Rehabilitation | D012046 | — | — | — | — | — | — | 3 | 3 |
| Peripheral nervous system diseases | D010523 | — | G64 | — | — | — | — | 3 | 3 |
| Acne vulgaris | D000152 | EFO_0003894 | L70 | — | — | — | — | 3 | 3 |
Show 156 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Triamcinolone acetonide |
| INN | triamcinolone |
| Description | Triamcinolone acetonide is a synthetic glucocorticoid that is the 16,17-acetonide of triamcinolone. Used to treat various skin infections. It has a role as an anti-inflammatory drug and an anti-allergic agent. It is an 11beta-hydroxy steroid, a 20-oxo steroid, a 21-hydroxy steroid, a 3-oxo-Delta(4) steroid, a glucocorticoid, a cyclic ketal, a fluorinated steroid and a primary alpha-hydroxy ketone. It is functionally related to a triamcinolone. It derives from a hydride of a pregnane. |
| Classification | Small molecule |
| Drug class | steroids (not prednisolone derivatives); topical steroids (acetal derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1 |
Identifiers
| PDB | — |
| CAS-ID | 76-25-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1504 |
| ChEBI ID | 71418 |
| PubChem CID | 6436 |
| DrugBank | DB00620 |
| UNII ID | F446C597KA (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Zilretta – Pacira BioSciences
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Zilretta – Flexion Therapeutics
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,533 documents
View more details
Safety
Black-box Warning
Black-box warning for: Blt-25 kit, Bupivilog kit, Mlk f1 kit, Mlk f3 kit, Mlk f4 kit, Mlk kit f2
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
22,403 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use